Creatine and Creatinine Metabolism - Physiological Reviews

More documents

Recommendations

Info

1194 MARKUS WYSS AND RIMA KADDURAH-DAOUK Volume 80 395. IENAGA K, NAKAMURA K, NAKA F, AND GOTO T. The metabolism of 1-methylhydantoin via 5-hydroxy-1-methylhydantoin in mammals. Biochim Biophys Acta 967: 441–443, 1988. 396. IENAGA K, NAKAMURA K, YAMAKAWA M, TOYOMAKI Y, MAT- SUURA H, YOKOZAWA T, OURA H, AND NAKANO K. The use of 13 C-labelling to prove that creatinine is oxidized by mammals into creatol and 5-hydroxy-1-methylhydantoin. J Chem Soc Chem Commun 509–510, 1991. 397. IM YS, CHIANG PK, AND CANTONI GL. Guanidoacetate methyltransferase. Purification and molecular properties. J Biol Chem 254: 11047–11050, 1979. 398. INANA G, HOTTA Y, ZINTZ C, CHAMBERS C, KENNAWAY NG, WELEBER RG, NAKAJIMA A, AND SHIONO T. Molecular basis of ornithine aminotransferase defect in gyrate atrophy. Prog Clin Biol Res 362: 191–219, 1991. 399. INGROSSO D, FOWLER AV, BLEIBAUM J, AND CLARKE S. Sequence of the D-aspartyl/L-isoaspartyl protein methyltransferase from human erythrocytes. Common sequence motifs for protein, DNA, RNA, and small molecule S-adenosylmethionine-dependent methyltransferases. J Biol Chem 264: 20131–20139, 1989. 400. INGWALL JS. The hypertrophied myocardium accumulates the MB-creatine kinase isozyme. Eur Heart J 5 Suppl F: 129–139, 1984. 401. INGWALL JS. Is cardiac failure a consequence of decreased energy reserve? Circulation 87 Suppl VII: VII-58–VII-62, 1993. 402. INGWALL JS. Whole-organ enzymology of the creatine kinase system in heart. Biochem Soc Trans 19: 1006–1010, 1991. 403. INGWALL JS, ATKINSON DE, CLARKE K, AND FETTERS JK. Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium. Eur Heart J 11 Suppl B: 108–115, 1990. 404. INGWALL JS AND FOSSEL ET. Changes in the creatine kinase system in the hypertrophied myocardium of the dog and rat. In: Perspectives in Cardiovascular Research, edited by N. R. Alpert. New York: Raven, 1983, p. 601–617. 405. INGWALL JS, KRAMER MF, FIFER MA, LORELL BH, SHEMIN R, GROSSMAN W, AND ALLEN PD. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 313: 1050–1054, 1985. 406. INGWALL JS AND WILDENTHAL K. Role of creatine in the regulation of cardiac protein synthesis. J Cell Biol 68: 159–163, 1976. 407. INOUYE Y, MATSUDA Y, NAID T, ARAI S, HASHIMOTO Y, ASANO K, OZAKI M, AND NAKAMURA S. Purification and characterization of creatinine amidohydrolase of Alcaligenes origin. Chem Pharm Bull 34: 269–274, 1986. 408. IPATA PL, MARMOCCHI F, MAGNI G, FELICIOLI R, AND POLI- DORO G. Baker’s yeast cytosine deaminase. Some enzymic properties and allosteric inhibition by nucleosides and nucleotides. Biochemistry 10: 4270–4276, 1971. 409. ISBRANDT D AND VON FIGURA K. Cloning and sequence analysis of human guanidinoacetate N-methyltransferase cDNA. Biochim Biophys Acta 1264: 265–267, 1995. 410. ISHIKAWA F, TAKAKU F, NAGAO M, OCHIAI M, HAYASHI K, TAKAYAMA S, AND SUGIMURA T. Activated oncogenes in a rat hepatocellular carcinoma induced by 2-amino-3-methyl-imidazo[4,5-f]quinoline. Jpn J Cancer Res 76: 425–428, 1985. 411. ISHIKAWA Y, SAFFITZ JE, MEALMAN TL, GRACE AM, AND ROB- ERTS R. Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma. Clin Chem 43: 467–475, 1997. 412. ISHIZAKI M, KITAMURA H, TAGUMA Y, AOYAGI K, AND NARITA M. Urinary excretion rate of guanidinoacetic acid as a sensitive indicator of early-stage nephropathy. In: Guanidino Compounds in Biology and Medicine, edited by P. P. De Deyn, B. Marescau, V. Stalon, and I. A. Qureshi. London: Libbey, 1992, p. 275–280. 413. ITO N, HASEGAWA R, IMAIDA K, TAMANO S, HAGIWARA A, HIROSE M, AND SHIRAI T. Carcinogenicity of 2-amino-1-methyl- 6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat. Mutat Res 376: 107–114, 1997. 414. IYENGAR MR, COLEMAN DW, AND BUTLER TM. Phosphocreatinine, a high-energy phosphate in muscle, spontaneously forms phosphocreatine and creatinine under physiological conditions. J Biol Chem 260: 7562–7567, 1985. 415. IYER GS, KRAHE R, GOODWIN LA, DOGGETT NA, SICILIANO MJ, FUNANAGE VL, AND PROUJANSKY R. Identification of a testis-expressed creatine transporter gene at 16p11.2 and confirmation of the X-linked locus to Xq28. Genomics 34: 143–146, 1996. 416. IZAWA S, HARADA N, WATANABE T, KOTOKAWA N, YAMAMOTO A, HAYATSU H, AND ARIMOTO-KOBAYASHI S. Inhibitory effects of food-coloring agents derived from Monascus on the mutagenicity of heterocyclic amines. J Agric Food Chem 45: 3980–3984, 1997. 417. JACKSON LS AND HARGRAVES WA. Effects of time and temperature on the formation of MeIQ x and DiMeIQ x in a model system containing threonine, glucose, and creatine. J Agric Food Chem 43: 1678–1684, 1995. 418. JACOBS I, BLEUE S, AND GOODMAN J. Creatine ingestion increases anaerobic capacity and maximum accumulated oxygen deficit. Can J Appl Physiol 22: 231–243, 1997. 419. JACOBSTEIN MD, GERKEN TA, BHAT AM, AND CARLIER PG. Myocardial protection during ischemia by prior feeding with the creatine analog cyclocreatine. J Am Coll Cardiol 14: 246–251, 1989. 420. JACOBUS WE, BITTL JA, AND WEISFELDT ML. Loss of mitochondrial creatine kinase in vitro and in vivo: a sensitive index of ischemic cellular and functional damage. In: Heart Creatine Kinase, edited by W. E. Jacobus and J. S. Ingwall. Baltimore, MD: Williams & Wilkins, 1980, p. 155–175. 421. JACOBUS WE AND SAKS VA. Creatine kinase of heart mitochondria: changes in its kinetic properties induced by coupling to oxidative phosphorylation. Arch Biochem Biophys 219: 167–178, 1982. 422. JAFFE M. Ueber den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. Hoppe-Seyler’s Z Physiol Chem 10: 391–400, 1886. 423. JÄGERSTAD M, LASER REUTERSWÄRD A, ÖSTE R, AND DAHL- QVIST A. Creatinine and Maillard reaction products as precursors of mutagenic compounds formed in fried beef. In: The Maillard Reaction in Foods and Nutrition, edited by G. R. Waller and M. S. Feather. Washington, DC: Am. Chem. Soc., 1983, p. 507–519. 424. JÄGERSTAD M, SKOG K, GRIVAS S, AND OLSSON K. Formation of heterocyclic amines using model systems. Mutat Res 259: 219– 233, 1991. 425. JANSSON E, SYLVÉN C, HENZE A, AND KAIJSER L. Myocardial enzyme activities in patients with mitral regurgitation or mitral stenosis. Cardiovasc Res 21: 202–207, 1987. 426. JAVIERRE C, LIZARRAGA MA, VENTURA JL, GARRIDO E, AND SEGURA R. Creatine supplementation does not improve physical performance in a 150 m race. J Physiol Biochem 53: 343–348, 1997. 427. JENNE DE, OLSEN AS, AND ZIMMER M. The human guanidinoacetate methyltransferase (GAMT) gene maps to a syntenic region on 19p13.3, homologous to band C of mouse chromosome 10, but GAMT is not mutated in jittery mice. Biochem Biophys Res Commun 238: 723–727, 1997. 428. JENNER P AND OLANOW CW. Understanding cell death in Parkinson’s disease. Ann Neurol 44 Suppl 1: S72–S84, 1998. 429. JENNINGS RB, REIMER KA, HILL ML, AND MAYER SE. Total ischemia in dog hearts, in vitro. 1. Comparison of high energy phosphate production, utilization, and depletion, and of adenine nucleotide catabolism in total ischemia in vitro vs severe ischemia in vivo. Circ Res 49: 892–900, 1981. 430. JENNINGS RB AND STEENBERGEN C. Nucleotide metabolism and cellular damage in myocardial ischemia. Annu Rev Physiol 47: 727–749, 1985. 431. JERNBERG-WIKLUND H, PETTERSSON M, AND NILSSON K. Recombinant interferon-� inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 46: 231–239, 1991. 432. JIAO Y, OKUMIYA T, SAIBARA T, TSUBOSAKI E, MATSUMURA H, PARK K, SUGIMOTO K, KAGEOKA T, AND SASAKI M. An enzymatic assay for erythrocyte creatine as an index of the erythrocyte life time. Clin Biochem 31: 59–65, 1998. 433. JINNAI D, MORI A, MUKAWA J, OHKUSU H, HOSOTANI M, MIZUNO A, AND TYE LC. Biochemical and physiological studies
July 2000 CREATINE AND CREATININE METABOLISM 1195 on guanidino compounds induced convulsions. Jpn J Brain Physiol 106: 3668–3673, 1969. 434. JOHANSSON MAE, FAY LB, GROSS GA, OLSSON K, AND JÄGER- STAD M. Influence of amino acids on the formation of mutagenic/ carcinogenic heterocyclic amines in a model system. Carcinogenesis 16: 2553–2560, 1995. 435. JOHANSSON MAE, FREDHOLM L, BJERNE I, AND JÄGERSTAD M. Influence of frying fat on the formation of heterocyclic amines in fried beefburgers and pan residues. Food Chem Toxicol 33: 993–1004, 1995. 436. JOHANSSON MAE AND JÄGERSTAD M. Occurrence of mutagenic/ carcinogenic heterocyclic amines in meat and fish products, including pan residues, prepared under domestic conditions. Carcinogenesis 15: 1511–1518, 1994. 437. JONES JD AND BURNETT PC. Implication of creatinine and gut flora in the uremic syndrome: induction of “creatininase” in colon contents of the rat by dietary creatinine. Clin Chem 18: 280–284, 1972. 438. JONES JD AND BURNETT PC. Creatinine metabolism in humans with decreased renal function: creatinine deficit. Clin Chem 20: 1204–1212, 1974. 439. JONES JD AND BURNETT PC. Creatinine metabolism and toxicity. Kidney Int 7 Suppl: S-294–S-298, 1975. 440. JONES RC AND WEISBURGER JH. Characterization of aminoalkylimidazol-4-one mutagens from liquid-reflux models. Mutat Res 222: 43–51, 1989. 441. JUHN MS AND TARNOPOLSKY M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 8: 286–297, 1998. 442. JUHN MS AND TARNOPOLSKY M. Potential side effects of oral creatine supplementation: a critical review. Clin J Sport Med 8: 298–304, 1998. 443. JUNG K, WESSLAU C, PRIEM F, SCHREIBER G, AND ZUBEK A. Specific creatinine determination in laboratory animals using the new enzymatic test kit “creatinine-PAP.” J Clin Chem Clin Biochem 25: 357–361, 1987. 444. KAASIK A, MINAJEVA A, DE SOUSA E, VENTURA-CLAPIER R, AND VEKSLER V. Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase. FEBS Lett 444: 75–77, 1999. 445. KABSCH W AND FRITZ-WOLF K. Mitochondrial creatine kinase—a square protein. Curr Opin Struct Biol 7: 811–818, 1997. 446. KADDURAH-DAOUK R, LILLIE JW, DAOUK GH, GREEN MR, KINGSTON R, AND SCHIMMEL P. Induction of a cellular enzyme for energy metabolism by transforming domains of adenovirus E1a. Mol Cell Biol 10: 1476–1483, 1990. 447. KADERLIK KR, MICHIN RF, MULDER GJ, ILETT KF, DAU- GAARD-JENSON M, TEITEL CH, AND KADLUBAR FF. Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. Carcinogenesis 15: 1703–1709, 1994. 448. KADERLIK KR, MULDER GJ, SHADDOCK JG, CASCIANO DA, TEITEL CH, AND KADLUBAR FF. Effect of glutathione depletion and inhibition of glucuronidation and sulfation on 2-amino-1methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism, PhIP- DNA adduct formation and unscheduled DNA synthesis in primary rat hepatocytes. Carcinogenesis 15: 1711–1716, 1994. 449. KADONO K, YAMAGUCHI T, TETSUTANI T, AND YASUNAGA K. Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading. Clin Chim Acta 209: 9–17, 1992. 450. KALDIS P, HEMMER W, ZANOLLA E, HOLTZMAN D, AND WAL- LIMANN T. “Hot spots” of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. Dev Neurosci 18: 542–554, 1996. 451. KAMMERMEIER H. Why do cells need phosphocreatine and a phosphocreatine shuttle. J Mol Cell Cardiol 19: 115–118, 1987. 452. KAMMERMEIER H, SCHMIDT P, AND JÜNGLING E. Free energy change of ATP-hydrolysis: a causal factor of early hypoxic failure of the myocardium? J Mol Cell Cardiol 14: 267–277, 1982. 453. KAMOUN PP, ZINGRAFF JJ, TURLIN G, AND LEBRETON P. Ascorbate-cyanide test on red blood cells in uremia: effect of guanidinopropionic acid. Nephron 28: 26–29, 1981. 454. KANAZAWA A, TANAKA A, IWATA S, SATOH S, HATANO E, SHINOHARA H, KITAI T, TSUNEKAWA S, IKAI I, YAMAMOTO M, TAKAHASHI R, CHANCE B, AND YAMAOKA Y. The beneficial effect of phosphocreatine accumulation in the creatine kinase transgenic mouse liver in endotoxin-induced hepatic cell death. J Surg Res 80: 229–235, 1998. 455. KANEKO M, MASUDA H, SUZUKI H, MATSUMOTO Y, KOBA- YASHI A, AND YAMAZAKI N. Modification of contractile proteins by oxygen free radicals in rat heart. Mol Cell Biochem 125: 163– 169, 1993. 456. KAPELKO VI, KUPRIYANOV VV, NOVIKOVA NA, LAKOMKIN VL, STEINSCHNEIDER AY, SEVERINA MY, VEKSLER VI, AND SAKS VA. The cardiac contractile failure induced by chronic creatine and phosphocreatine deficiency. J Mol Cell Cardiol 20: 465–479, 1988. 457. KAPELKO VI, SAKS VA, NOVIKOVA NA, GOLIKOV MA, KUPRIY- ANOV VV, AND POPOVICH MI. Adaptation of cardiac contractile function to conditions of chronic energy deficiency. J Mol Cell Cardiol 21 Suppl I: 79–83, 1989. 458. KAPELKO VI, VEKSLER VI, POPOVICH MI, AND VENTURA- CLAPIER R. Energy-linked functional alterations in experimental cardiomyopathies. Am J Physiol Heart Circ Physiol 261: H39– H44, 1991. 459. KAPLAN A AND NAUGLER D. Creatinine hydrolase and creatine amidinohydrolase. I. Presence in cell-free extracts of Arthrobacter ureafaciens. Mol Cell Biochem 3: 9–15, 1974. 460. KAPLAN A AND SZABO LL. Creatinine hydrolase and creatine amidinohydrolase. II. Partial purification and properties. Mol Cell Biochem 3: 17–25, 1974. 461. KAPLAN LJ, BLUM H, BANERJEE A, AND WHITMAN GJR. Protecting myocardial creatine kinase activity during reperfusion improves bioenergetics and contractile function. J Surg Res 54: 311–315, 1993. 462. KAPLAN LJ, BLUM H, BELLOWS ALM, BANERJEE A, AND WHIT- MAN GJR. Reversible injury: creatine kinase recovery restores bioenergetics and function. J Surg Res 62: 103–108, 1996. 463. KARPATI G, CARPENTER S, LARBRISSEAU A, AND LAFON- TAINE R. The Kearns-Shy syndrome. A multisystem disease with mitochondrial abnormality demonstrated in skeletal muscle and skin. J Neurol Sci 19: 133–151, 1973. 464. KARPATI G, CARPENTER S, MELMED C, AND EISEN AA. Experimental ischemic myopathy. J Neurol Sci 23: 129–161, 1974. 465. KATO T, HARASHIMA T, MORIYA N, KIKUGAWA K, AND HIRAMOTO K. Formation of the mutagenic/carcinogenic imidazoquinoxaline-type heterocyclic amines through the unstable free radical Maillard intermediates and its inhibition by phenolic antioxidants. Carcinogenesis 17: 2469–2476, 1996. 466. KATO T, SHIOIRI T, MURASHITA J, HAMAKAWA H, INUBUSHI T, AND TAKAHASHI S. Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res Neuroimag 61: 151–160, 1995. 467. KATO T, SHIOIRI T, MURASHITA J, HAMAKAWA H, TAKAHASHI Y, INUBUSHI T, AND TAKAHASHI S. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31 P-MRS. Psychol Med 25: 557–566, 1995. 468. KATSURAGI T, SAKAI T, MATSUMOTO K, AND TONOMURA K. Cytosine deaminase from Escherichia coli: production, purification, and some characteristics. Agric Biol Chem 50: 1721–1730, 1986. 469. KATSURAGI T, SONODA T, MATSUMOTO K, SAKAI T, AND TONOMURA K. Purification and some properties of cytosine deaminase from baker’s yeast. Agric Biol Chem 53: 1313–1319, 1989. 470. KATZ LA, SWAIN JA, PORTMAN MA, AND BALABAN RS. Relation between phosphate metabolites and oxygen consumption of heart in vivo. Am J Physiol Heart Circ Physiol 256: H265–H274, 1989. 471. KELLER JN, PANG Z, GEDDES JW, BEGLEY JG, GERMEYER A, WAEG G, AND MATTSON MP. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid �-peptide: role of
Page 1 and 2:
PHYSIOLOGICAL REVIEWS Vol. 80, No.
Page 3 and 4:
July 2000 CREATINE AND CREATININE M
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38: July 2000 CREATINE AND CREATININE M
Page 87: July 2000 CREATINE AND CREATININE M
Page 107: July 2000 CREATINE AND CREATININE M
show all

Creatine and Creatinine Metabolism - Physiological Reviews

Create successful ePaper yourself

Delete template?

Save as template?